Table 2.
Laboratory Features of 44 Patients with Suspected Anabolic Steroid Jaundice
| Feature | Number Positive or median | Proportion or range |
|---|---|---|
| Initial values at onset | ||
| ALT (U/L) | 169 | 61–1254 |
| AST (U/L) | 82 | 38–278 |
| Alk Phos (U/L) | 111 | 53–461 |
| Bilirubin (mg/dL) | 9.8 | 4.1–45.7 |
| R Value | ||
| Injury Pattern* [n=42] | ||
| Cholestatic | 12 | 29% |
| Mixed | 13 | 31% |
| Hepatocellular | 17 | 41% |
| Peak values during course | ||
| ALT (U/L) | 189 | 64–1254 |
| AST (U/L) | 128 | 55–472 |
| Alk Phos (U/L) | 257 | 83–625 |
| Bilirubin (mg/dL) | 25.8 | 7.3–63.0 |
| INR | 1.1 | 0.9–2.1 |
| Duration of abnormalities | ||
| Bilirubin ≥ 2.5 mg/dL↑ (days) (n=36) | 94.3 | 34–459 |
| Chronic lab abnormalities* | ||
| 6 months [n=31]+ | 4 | 39%+ |
| 12 months [n=12] | 2 | 50%± |
| 24 months [n=2] | 2 | 100%± |
| Other Investigations or interventions | ||
| MRCP or ERCP | 9 | 20% |
| Liver biopsy | 22 | 50% |
| Corticosteroid therapy [n=43] | 7 | 16% |
| Ursodiol therapy at time of enrollment | 21 | 47% |
| Creatinine > 1.5 mg/dL | 6 | 14% |
| Causality, Severity and Outcomes | ||
| Severity score | ||
| 1 (mild, anicteric) | 0 | 0% |
| 2 (moderate, icteric) | 10 | 23% |
| 3 (moderate, hospitalized) | 25 | 57% |
| 4 (severe, organ failure) | 9 | 21% |
| 5 (fatal or liver transplant) | 0 | 0% |
| Causality scores | ||
| Definite | 25 | 57% |
| Highly likely | 19 | 43% |
| Probable | 0 | 0% |
Data not available on all 44 patients; number given in brackets.
*
Chronicity defined as any abnormal of serum ALT, T Bili or Alk Phos 6 months after presentation
↑
Only 36 subjects whose duration can be calculated with observed bilirubin level < 2.5
+
Only 16 of the patients came for their 6 month follow up
±
Percentage of chronic patients at 6 months followed up at 12 and 24 months